Amended Current Report Filing (8-k/a)
June 15 2020 - 4:20PM
Edgar (US Regulatory)
0001549084
false
0001549084
2020-06-09
2020-06-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
June 10, 2020
Ekso Bionics Holdings, Inc.
(Exact Name of Registrant as specified in
its charter)
Nevada
|
|
001-37854
|
|
99-0367049
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices,
including zip code)
(510) 984-1761
(Registrant’s telephone number, including
area code)
Not Applicable
(Registrant’s former name or former
address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
|
EKSO
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
EXPLANATORY NOTE
On
June 10, 2020, Ekso Bionics Holdings, Inc. (the “Company”) filed a current report on Form 8-K (the “Original
Report”) to report the closing of a registered direct offering by the Company.
This
current report on Form 8-K/A amends Item 8.01 – Other Events – to the Original Report, based on the finalization of
a warrant exercise price adjustment, which became determinable as of the close of trading on June 12, 2020, and should be read
in conjunction with the Original Report. Except as stated above, no other information contained in the Original Report has been
amended.
On
May 24, 2019, the Company issued warrants to purchase up to 444,444 (as adjusted to give effect to a 1-for-15 reverse stock split
effective March 24, 2020) shares of Common Stock (the “May 2019 Warrants”). Immediately prior to the Offering,
the May 2019 Warrants had an exercise price of $5.70 per share. The May 2019 Warrants include a price-based anti-dilution adjustment
provision. Accordingly, as a result of the Offering, the exercise price of the May 2019 Warrants was decreased to the price per
share of $3.52. This amount is equal to the lower of (x) the consideration paid for the securities issued in this offering, or
$4.5145 per share, (y) the lowest exercise price of the Warrants, or $5.18, and (z) the lowest one-day volume-weighted average
price of the Common Stock on the Nasdaq Capital Market as measured each day during the five trading day period starting on June
8, 2020, rounded to the nearest cent, or $3.52.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
EKSO BIONICS HOLDINGS, INC.
|
|
|
|
|
|
By:
|
|
/s/ John Glenn
|
|
Name:
|
John Glenn
|
|
Title:
|
Chief Financial Officer
|
Dated: June 15, 2020
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024